Clinical Trials Logo

Filter by:
NCT ID: NCT05871099 Recruiting - Gastric Cancer Clinical Trials

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Start date: November 20, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6~8 cycles.

NCT ID: NCT05870995 Recruiting - Refractory Leukemia Clinical Trials

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.

NCT ID: NCT05870969 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

dSEARCH
Start date: March 1, 2023
Phase:
Study type: Observational

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

NCT ID: NCT05870917 Recruiting - Clinical trials for Plasma Cell Leukemia

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Start date: April 25, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.

NCT ID: NCT05870696 Recruiting - Colorectal Adenoma Clinical Trials

the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening

Start date: April 30, 2023
Phase:
Study type: Observational

This study is to Evaluate the diagnostic sensitivity of the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer. There are two steps in this study. Firstly, the diagnostic model is established based on tumor-specific and gut-microbiome related serum metabolites. Secondly, the sensitivity, specificity and accuracy of the diagnostic model is evaluated in detecting advanced adenoma and colorectal cancer stages in an independent multi-centered cohort.

NCT ID: NCT05870683 Recruiting - Clinical trials for Helicobacter Pylori Infection

Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection (SHARE2301)

Start date: May 24, 2023
Phase: N/A
Study type: Interventional

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of stomach cancer. Progressive application of dual therapy for the eradication of Helicobacter pylori. Tegoprazan, a Potassium-Competitive Acid Blockers. The efficacy of P-CAB agents represented by vonoprazan in H. pylori eradication therapy has been widely verified.

NCT ID: NCT05870514 Recruiting - Critical Illness Clinical Trials

Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of fospropofol disodium for injection compared to propofol for deep sedation in mechanically ventilated ICU patients.

NCT ID: NCT05870475 Recruiting - Polycythemia Vera Clinical Trials

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

PV
Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

NCT ID: NCT05870436 Recruiting - Asthma Clinical Trials

A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population

Start date: May 19, 2023
Phase:
Study type: Observational

This study was a multicenter, open, observational study and was divided into two stages; Stage I study includes patients with suspected asthma to observe the diagnostic value and safety of Methacholine Choline Provocation Test. All patients clinically evaluated for bronchial provocation testing were included in the stage II study to further validate the diagnostic value and cutoff value of the methacholine choline provocation test.

NCT ID: NCT05870397 Recruiting - Clinical trials for Helicobacter Pylori Eradication

Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial

Start date: April 21, 2023
Phase: N/A
Study type: Interventional

Although Urea breath test has been commonly used to recheck the efficiency of Helicobacter pylori eradication, there has been no randomized trials comparing the accuracy of Urea breath test results at different times after eradication. The investigators aim to assess the accuracy and influence factors of post-therapy test at different times and follow up the cut off samples to optimize the best time to recheck.